alnylam
Alnylam is seeking a Metabolomics Scientist to design, validate, and apply LC‑MS/MS methods for metabolite and lipid quantification, supporting biomarker discovery and target validation for RNAi therapeutics. The role involves end‑to‑end sample preparation, instrument operation, bioinformatics data analysis, and collaboration with cross‑disciplinary teams in preclinical and clinical drug discovery.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
Senior Laboratory Research Scientist - Metabolomics/Lipidomics Specialist
UK Centre for Ecology and Hydrology
Metabolomics Platform Research Associate
University of Chicago
Metabolomics Laboratory Technician
Colorado State University
Technical Support Specialist - Metabolomics Kits
Metabolon, Inc.
Analytical Chemist Metabolomics
Syngenta Group
Associate Principal Scientist - Spatial multi-omics
bayer